[1] Solomon B., et al. Phase 2 Study of Lorlatinib in Patients with Advanced ALK+ /ROS1+ Non-Small-Cell Lung Cancer. As presented at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer. October 16, 2017. Abstract #OA 05.06.
[2] The International Agency for Research on Cancer, the World Health Organization, GLOBOCAN 2008, Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (select ?Lung? from the drop-down menu). Accessed February 2018.
[3] Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics. 2009; 3: 215?224.
[4] Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005; 128 (1):452?462.
[5] American Cancer Society. Detailed Guide: Lung Cancer (Non-Small Cell). Available at: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-…. Accessed February 2018.
[6] Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
[7] Gu?rin A, Sasane M, Zhang J et al. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. Cancer Epidemiol. 2015 Jun; 39(3): 307-12. doi: 10.1016.
[8] Garber K. ALK, lung cancer, and personalized therapy: portent of the future? J Natl Cancer Inst. 2010;102:672-675.
Home Solomon B., et al. Phase 2 Study of Lorlatinib in Patients
